News | Proton Therapy | May 31, 2018

Beaumont Researchers Invent New Mode of Proton Treatment for Lung Cancer

Continuous arc treatment significantly reduces adverse effects of respiration-induced motion on lung cancer patients

Beaumont Researchers Invent New Mode of Proton Treatment for Lung Cancer

May 31, 2018 — Members of Beaumont Health’s proton therapy team presented research on a new treatment for patients with lung cancer at the recent European Society for Radiotherapy and Oncology (ESTRO) 37 Congress, April 20-24 in Barcelona, Spain.

“Beaumont researchers have invented a new mode of proton therapy for lung cancer,” said Peyman Kabolizadeh, M.D., Ph.D., clinical director, Beaumont Proton Therapy Center in Royal Oak. “A continuous proton arc treatment can significantly reduce the adverse effects of respiration-induced motion on lung cancer treatments. This advancement will also result in a better and lower dose of radiation to adjacent organs.”

Explained Kabolizadeh, “The promising results might lead to interest and future development of the proton arc therapy technique. Beaumont continues to be a center of new treatment development through research.”

Proton therapy is a high-tech alternative to X-ray radiation. A scanning beam of proton radiation with online image guidance offers greater precision to destroy cancerous cells, sparing adjacent healthy tissue with fewer side effects.

Proton therapy uses positively charged atomic particles, traveling up to two-thirds the speed of light, to fight cancer. A cyclotron, or particle accelerator, creates protons from hydrogen molecules. The proton beam is sent to the treatment room through a transport system consisting of magnets, called the beam line, finally arriving in the gantry, a device that rotates around the patient. The beam is directed to the patient through a nozzle that targets the tumor.

While proton therapy is not effective against all cancers, it is effective in treating many solid and localized tumors.

Beaumont’s center is one of just 28 proton therapy centers in the U.S. It is the only operational proton therapy center in Michigan. Beaumont doctors have treated or consulted with patients across Michigan and 11 other states since opening the Proton Therapy Center in 2017.

“Our IBA Proteus One single-room treatment system includes precision technologies,” said Kabolizadeh. “Intensity modulated proton therapy with pencil beam scanning technology and 3-D cone beam CT [computed tomography], can target a tumor within less than a millimeter.”

Pencil beam scanning (PBS) refers to the delivery of protons in a thin beam. Like a pencil, the beam uses back and forth motions to target the treatment area – the shape, size and depth — painting a radiation dose on tumors layer by layer. Compared to X-ray beams, which pass through a patient, proton beams deliver targeted radiation to the tumor and then stop – resulting in no exit dose.

For more information: www.beaumont.org

Related Content

Vinai Gondi, M.D., the Director of Research at the Northwestern Medicine Chicago Proton Center, Co-director of the Brain Tumor Center at Northwestern Medicine Cancer Center, Warrenville, and lead author of the NRG-BN001 abstract.

Vinai Gondi, M.D., Director of Research at the Northwestern Medicine Chicago Proton Center, Co-director of the Brain Tumor Center at Northwestern Medicine Cancer Center, Warrenville, and lead author of the NRG-BN001 abstract.

News | Intensity Modulated Radiation Therapy (IMRT) | October 27, 2020
October 27, 2020 — A...
"Stereotactic radiosurgery versus whole-brain radiation therapy for patients with 4-15 brain metastases: A phase III randomized controlled trial" was presented by Jing Li, M.D., The University of Texas MD Anderson Cancer Center, at ASTRO20
News | Stereotactic Body Radiation Therapy (SBRT) | October 26, 2020
October 26, 2020 — Results of a new randomized phase III trial suggest that...
"Stereotactic ablative fractionated radiotherapy versus radiosurgery for oligometastatic neoplasia to the lung: A randomised phase II trial," presented by Shankar Siva, Ph.D., Peter MacCallum Cancer Centre, was presented at ASTRO20
News | Stereotactic Body Radiation Therapy (SBRT) | October 26, 2020
October 26, 2020 — A new study, conducted across 13 medical centers in Australia and New Zealand, strengthens the cas
"Initial report of a randomized trial comparing conventional- vs conventional plus fluciclovine (18F) PET/CT imaging-guided post-prostatectomy radiotherapy for prostate cancer" was presented by Ashesh Jani, M.D., Winship Cancer Institute of Emory University, at ASTRO20
News | PET Imaging | October 26, 2020
October 26, 2020 — Adding the advanced PET radiotracer...
A randomized phase II/III study comparing 24Gy in 2 stereotactic body radiotherapy (SBRT) fractions versus 20Gy in 5 conventional palliative radiotherapy (CRT) fractions for patients with painful spinal metastases was presented by Arjun Sahgal, M.D., University of Toronto, today at ASTRO20
News | Radiation Therapy | October 26, 2020
October 26, 2020 — A new study shows using fewer and higher doses of high-precision...
Nearly 40 MRIdian-focused presentations will be part of the ASTRO Scientific Sessions
News | Magnetic Resonance Imaging (MRI) | October 26, 2020
October 26, 2020 — ViewRay, Inc. announced that the company's MRIdian Linac MRI-guided radiation therapy system will
Treating lung cancer patients with proton therapy may help reduce the risk of radiation-induced heart diseases, suggests a new study from Penn Medicine. In a retrospective trial of more than 200 patients, mini-strokes were significantly less common among patients who underwent proton therapy versus conventional photon-based radiation therapy. Proton therapy patients also experienced fewer heart attacks.
News | Proton Therapy | October 25, 2020
October 25, 2020 — Treating lung cancer patients with prot...
Radiation Oncology Orchestrator (IntelliSpace Radiation Oncology) and Practice Management can reduce the time from patient referral to the start of treatment by up to half
News | Radiation Oncology | October 25, 2020
October 25, 2020 —Philips, a global leader in health technology, will showcase its latest advances in ...